Marker Therapeutics, Inc.

News

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Read More

Adoptive “Non-Engineered” T-Cell Therapy Shows Preliminary Efficacy in Lymphomas

Researchers from Baylor College of Medicine and Texas Children’s Hospital are exploring “non-engineered” T-cell therapies that are easier to manufacture and able to target multiple antigens.
Read More

Houston: One of the Fastest-Growing Life Science Communities

A recent report by CBRE Research analyzing U.S. life science clusters found that Houston, Texas is the third-fastest growing life science market from 2014 to 2017.
Read More

Marker Therapeutics Rockets After CEO Says Phase 2 Leukemia Trial with T-cell Therapy in Works

With the help of Marker's technology, a population of T-cells attacks multiple cancer targets and works to activate a patient's immune system to trigger anti-tumor activity.
Read More

Marker Therapeutics Provides Business and Clinical Update

Company to host business update call and webcast today at 5:00 p.m. EDT
Read More

Marker Therapeutics to Host Business Update Conference Call and Webcast on Thursday, March 28th

Marker Therapeutics announces business update conference call and webcast on Thursday, March 28th.
Read More

Marker Therapeutics: Phenomenal Data In Lymphoma And Other Indications, Yet Little Recognition From The Street

DLBCL data was particularly impressive. Patients who were third and fourth line refractory and relapsed post-transplant are experiencing durable and long responses with some now five years in remission.
Read More

Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019

Marker Therapeutics announces updated data from four clinical trials using the Company’s multi-antigen targeted T cell (MultiTAA) therapies.
Read More

Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon), on Receiving the ASBMT Lifetime Achievement Award

Marker Therapeutics would like to congratulate Scientific Advisory Board Member, Helen E. Heslop, MD, DSc (Hon), on receiving the ASBMT Lifetime Achievement Award.
Read More

Marker Therapeutics to Present at the CAR-TCR Summit Europe

President and CEO, Peter L. Hoang, and Chief Development Officer, Dr. Juan Vera, will be presenting at the CAR-TCR Summit Europe.
Read More